[PDF][PDF] Characterization of CD4CD25 regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
GC Cesana, G DeRaffele, S Cohen, D Moroziewicz… - J Clin …, 2006 - researchgate.net
J Clin Oncol, 2006•researchgate.net
Characterization of CD4 CD25 Regulatory T Cells in Patients Treated With High-Dose
Interleukin-2 for Metastatic Melanoma or Rena Page 1 Characterization of CD4 CD25
Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or
Renal Cell Carcinoma Giovanni C. Cesana, Gail DeRaffele, Seth Cohen, Dorota Moroziewicz,
Josephine Mitcham, John Stoutenburg, Ken Cheung, Charles Hesdorffer, Seunghee
Kim-Schulze, and Howard L. Kaufman A B S T R A C T Purpose To characterize the number and …
Interleukin-2 for Metastatic Melanoma or Rena Page 1 Characterization of CD4 CD25
Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or
Renal Cell Carcinoma Giovanni C. Cesana, Gail DeRaffele, Seth Cohen, Dorota Moroziewicz,
Josephine Mitcham, John Stoutenburg, Ken Cheung, Charles Hesdorffer, Seunghee
Kim-Schulze, and Howard L. Kaufman A B S T R A C T Purpose To characterize the number and …
Purpose
To characterize the number and functional status of CD4 CD25 regulatory T cells (Tregs) in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) treated with high-dose bolus interleukin-2 (IL-2).
researchgate.net